EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Adeno-Associated Virus Gene Therapy: Translational Progress and Future Prospects in the Treatment of Heart Failure



Adeno-Associated Virus Gene Therapy: Translational Progress and Future Prospects in the Treatment of Heart Failure



Heart, Lung & Circulation: -



Despite advances in treatment over the past decade, heart failure remains a significant public health burden and a leading cause of death in the developed world. Gene therapy provides a promising approach for preventing and reversing cardiac abnormalities, however, clinical application has shown limited success to date. A substantial effort is being invested into the development of recombinant adeno-associated viruses (AAVs) for cardiac gene therapy as AAV gene therapy offers a high safety profile and provides sustained and efficient transgene expression following a once-off administration. Due to the physiological, anatomical and genetic similarities between large animals and humans, preclinical studies using large animal models for AAV gene therapy are crucial stepping stones between the laboratory and the clinic. Many molecular targets selected to treat heart failure using AAV gene therapy have been chosen because of their potential to regulate and restore cardiac contractility. Other genes targeted with AAV are involved with regulating angiogenesis, beta-adrenergic sensitivity, inflammation, physiological signalling and metabolism. While significant progress continues to be made in the field of AAV cardiac gene therapy, challenges remain in overcoming host neutralising antibodies, improving AAV vector cardiac-transduction efficiency and selectivity, and optimising the dose, route and method of delivery.

(PDF emailed within 0-6 h: $19.90)

Accession: 045024266

Download citation: RISBibTeXText

PMID: 29703647

DOI: 10.1016/j.hlc.2018.03.005



Related references

Gene therapy progress and prospects: Recombinant adeno-associated virus (rAAV) vectors. Gene Therapy 11(10): 805-810, 2004

The future of epilepsy treatment: focus on adeno-associated virus vector gene therapy. Drug News & Perspectives 23(5): 281-286, 2010

Altered beta-adrenergic receptor signaling in heart failure, in vivo gene transfer via adeno and adeno-associated virus. Microcirculation 3(2): 225-228, 1996

Chronic heart failure: progress in diagnosis and treatment. Topics: III. Progress in prevention, control and treatment: 8. Establishment of novel therapy for congestive heart failure using human iPS cell-derived regenerated cardiomyocytes. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 101(2): 415-423, 2012

Translational Aspects of Adeno-Associated Virus-Mediated Cardiac Gene Therapy. Human Gene Therapy 29(12): 1341-1351, 2018

Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 119(1): 89-98, 2009

Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs. Human Gene Therapy. Clinical Development 26(1): 5-14, 2015

Gene therapy and the adeno-associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: Trials, future directions and safety considerations. Clinical & Experimental Ophthalmology 2018: -, 2018

Prospects for the use of adeno-associated virus as a vector for human gene therapy. Human Gene Therapy 5(7): 793-801, 1994

Chronic heart failure: progress in diagnosis and treatment. Topics: III. Progress in prevention, control and treatment: 3. Evidence-based pharmacologic therapy for chronic heart failure. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 101(2): 379-386, 2012

Chronic heart failure: progress in diagnosis and treatment. Topics: III. Progress in prevention, control and treatment: 4. Pharmacologic therapy: antiarrhythmic drug therapy. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 101(2): 387-394, 2012

Adeno-associated virus vector-mediated bcl-2 gene transfer into post-ischemic gerbil brain in vivo: Prospects for gene therapy of ischemia-induced neuronal death. Gene Therapy 7(14): 1244-1249, July, 2000

Retinal Gene Therapy: Current Progress and Future Prospects. Expert Review of Ophthalmology 10(3): 281-299, 2015

Ocular gene therapy: current progress and future prospects. Trends in Molecular Medicine 15(1): 23-31, 2009

Progress with Recombinant Adeno-Associated Virus Vectors for Gene Therapy of Alpha-1 Antitrypsin Deficiency. Human Gene Therapy Methods 26(3): 77-81, 2016